ScripBiotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b
ScripDrug access and supply-chain issues have remained challenging in the aftermath of the COVID-19 pandemic, while increasing research and development in the cell and gene therapy fields are expected to y
ScripSome three years after COVID-19 kickstarted a massive adoption of digital technology and shift to remote monitoring in clinical development, technology continues to effect seismic changes in the trial
ScripIn the previous installment of Scrip Asks…What Does 2023 Hold For Biopharma? , we asked what technological advance would have the biggest impact on biopharma in 2023. Artificial intelligence was a fe